RFPL1

Across TCGA pan-cancer cohorts, RFPL1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RFPL1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RFPL1 RNA is repressed in tumor relative to normal tissue. In most cancer types RFPL1 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, BRCA, and KIRC are the cancer types where RFPL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFPL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−0.203	<.001	8	view →
BRCA	Female	II,III,IV	+0.063	<.001	6	view →
KIRC	Female	All	+0.018	.009	3	view →
CHOL	All	All	−0.335	.012	2	view →
PRAD	All	All	−0.207	.028	2	view →
LUSC	All	All	+0.071	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RFPL1–LIHC

Open the LIHC breakdown →